PE20040840A1 - Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih - Google Patents
Derivados de 4-oxoquinolina como inhibidores de la integrasa del vihInfo
- Publication number
- PE20040840A1 PE20040840A1 PE2003001176A PE2003001176A PE20040840A1 PE 20040840 A1 PE20040840 A1 PE 20040840A1 PE 2003001176 A PE2003001176 A PE 2003001176A PE 2003001176 A PE2003001176 A PE 2003001176A PE 20040840 A1 PE20040840 A1 PE 20040840A1
- Authority
- PE
- Peru
- Prior art keywords
- group
- inhibitors
- dihydroquinoline
- dichlorobenzyl
- oxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE 4-OXOQUINOLINA DE FORMULA I DONDE EL ANILLO Cy ES UN GRUPO DE ANILLO DE CARBONO DE C3-C10 OPCIONALMENTE SUSTITUIDO CON 1-5 SUSTITUYENTES SELECCIONADOS DEL GRUPO A SELECCIONADO DE FENILO, NITRO, HALOGENO, ALQUILO C1-C4 ENTRE OTROS O HETEROCICLICO CON HETEROATOMOS; R1 ES UN GRUPO B SELECCIONADO DE UN GRUPO DE ANILLO DE CARBONO DE C3-C10 CON 1 A 5 SUSTITUYENTES O UN GRUPO ALQUILO C1-C10 CON 1 A 3 SUSTITUYENTES SELECCIONADOS DE HALOGENO; R2 ES H, ALQUILO C1-C4; R31 ES H, CIANO, OH, AMINO, NITRO, HALO, ENTRE OTROS; X ES C-R32, N; Y ES CR33, N DONDE R32 Y R33 SON H, CIANO, NITRO, HALO ENTRE OTROS. SON COMPUESTOS PREFERIDOS ACIDO 6-(2,3-DICLOROBENCIL)-1-(2-HIDROXIETIL)-4-OXO-1,4-DIHIDROQUINOLINA-3-CARBOXILICO, ACIDO 6-(2,3-DICLOROBENCIL)-8-FLUORO-1-(2-HIDROXIETIL)-4-OXO-1,4-DIHIDROQUINOLINA-3-CARBOXILICO, ACIDO 6-(2,3-DICLOROBENCIL)-1-(2-METANOSULFONILAMINOETIL)-4-OXO-1,4-DIHIDROQUINOLINA-3-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA INTEGRASA DEL VIH
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002336843 | 2002-11-20 | ||
JP2003065807 | 2003-03-11 | ||
JP2003139616 | 2003-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040840A1 true PE20040840A1 (es) | 2004-12-30 |
Family
ID=32329647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003001176A PE20040840A1 (es) | 2002-11-20 | 2003-11-20 | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih |
Country Status (32)
Country | Link |
---|---|
US (6) | US7176220B2 (es) |
EP (5) | EP2272516A3 (es) |
KR (1) | KR100665919B1 (es) |
AR (2) | AR042095A1 (es) |
AT (1) | ATE443048T1 (es) |
AU (1) | AU2003302029B8 (es) |
BE (1) | BE2013C063I2 (es) |
BR (1) | BRPI0306214B1 (es) |
CA (1) | CA2470365C (es) |
CY (2) | CY1110690T1 (es) |
CZ (1) | CZ2004764A3 (es) |
DE (1) | DE60329318D1 (es) |
DK (1) | DK1564210T5 (es) |
ES (1) | ES2329240T3 (es) |
FR (1) | FR13C0061I2 (es) |
HK (1) | HK1080852A1 (es) |
HU (1) | HUS1300066I1 (es) |
IL (2) | IL162548A0 (es) |
LT (1) | LTPA2013018I1 (es) |
LU (1) | LU92307I2 (es) |
MX (1) | MXPA04006553A (es) |
MY (1) | MY136173A (es) |
NO (3) | NO327098B1 (es) |
NZ (1) | NZ533641A (es) |
PE (1) | PE20040840A1 (es) |
PT (1) | PT1564210E (es) |
SI (1) | SI1564210T1 (es) |
SK (1) | SK2662004A3 (es) |
TR (1) | TR200401663T1 (es) |
TW (1) | TWI248928B (es) |
WO (1) | WO2004046115A1 (es) |
ZA (1) | ZA200404537B (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA007060B1 (ru) | 2001-10-26 | 2006-06-30 | Иституто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы |
SK2662004A3 (sk) * | 2002-11-20 | 2005-06-02 | Japan Tobacco, Inc. | Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz |
ATE482208T1 (de) | 2004-03-10 | 2010-10-15 | Us Of America Represented By T | Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids- related complex (arc) |
MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
EP2332538A1 (en) * | 2004-05-21 | 2011-06-15 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
US7745459B2 (en) | 2004-09-21 | 2010-06-29 | Japan Tobacco Inc. | Quinolizinone compound and use thereof as HIV integrase inhibitor |
WO2006033422A1 (ja) * | 2004-09-21 | 2006-03-30 | Japan Tobacco Inc. | キノリジノン化合物、およびそのhivインテグラーゼ阻害剤としての利用 |
UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US20070032522A1 (en) * | 2005-07-01 | 2007-02-08 | Kumar Dange V | Antiviral agents |
WO2007063869A1 (ja) * | 2005-11-30 | 2007-06-07 | Japan Tobacco Inc. | 高純度キノロン化合物の製造方法 |
EA201201496A1 (ru) * | 2005-12-30 | 2013-07-30 | Джилид Сайэнс, Инк. | Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты) |
US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
AU2013203476C1 (en) * | 2005-12-30 | 2016-11-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
JP2009525261A (ja) * | 2006-02-01 | 2009-07-09 | 日本たばこ産業株式会社 | レトロウイルス感染症の治療のための、6−(3−クロロ−2−フルオロベンジル)−1−[(2s)−1−ヒドロキシ−3−メチルブタン−2−イル]−7−メトキシ−4−オキソ−1,4−ジヒドロキノリン−3−カルボン酸またはその塩の使用 |
WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
AP2914A (en) * | 2006-03-06 | 2014-05-31 | Japan Tobacco Inc | Method for producing 4-oxoquinoline compound |
WO2007102499A1 (ja) * | 2006-03-06 | 2007-09-13 | Japan Tobacco Inc. | 4-オキソキノリン化合物の製造方法 |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
EA020489B1 (ru) | 2006-07-07 | 2014-11-28 | Джилид Сайэнс, Инк. | Модуляторы фармакокинетических свойств лекарственных средств |
US7888375B2 (en) | 2006-07-19 | 2011-02-15 | The University Of Georgia Research Foundation, Inc | Pyridinone diketo acids: inhibitors of HIV replication |
WO2008033836A2 (en) | 2006-09-12 | 2008-03-20 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
KR20090077813A (ko) | 2006-09-29 | 2009-07-15 | 아이데닉스 파마슈티칼스, 인코포레이티드 | Hiv 억제제로서의 거울상이성질체적으로 순수한 포스포인돌 |
DE602007012308D1 (de) | 2006-12-22 | 2011-03-10 | Avexa Ltd | Bicyclische pyrimidinone und deren verwendung |
SG183059A1 (en) * | 2007-02-23 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
NZ582089A (en) * | 2007-06-29 | 2013-01-25 | Gilead Sciences Inc | Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir |
AR067183A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Composiciones terapeuticas y metodos, usos y equipos |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
AU2008299931B2 (en) | 2007-09-12 | 2013-01-10 | Concert Pharmaceuticals, Inc. | Deuterated 4 -oxoquinoline derivatives for the treatment of HIV infection |
US8377960B2 (en) * | 2007-11-15 | 2013-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
CN101918365B (zh) | 2007-11-16 | 2013-10-09 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
AU2008350907A1 (en) | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
WO2009089263A2 (en) * | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
PL2296633T3 (pl) * | 2008-05-02 | 2016-03-31 | Gilead Sciences Inc | Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego |
WO2010073078A2 (en) * | 2008-12-22 | 2010-07-01 | Orchid Research Laboratories Ltd. | Heterocyclic compounds as hdac inhibitors |
MX2011008289A (es) * | 2009-02-06 | 2011-09-15 | Gilead Sciences Inc | Tabletas para terapia combinada. |
EP2395983B1 (en) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
WO2010137032A2 (en) * | 2009-05-14 | 2010-12-02 | Matrix Laboratories Ltd. | Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts |
WO2011004389A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of elvitegravir |
EP2470014A4 (en) * | 2009-08-26 | 2013-01-16 | Merck Sharp & Dohme | HIV integrase inhibitors |
MX2012002942A (es) | 2009-09-30 | 2012-04-11 | Boehringer Ingelheim Int | Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno. |
KR101813025B1 (ko) | 2009-09-30 | 2017-12-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실치환된 벤질벤젠 유도체의 제조방법 |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
CN102574854B (zh) | 2009-10-13 | 2014-04-16 | 伊兰科动物健康爱尔兰有限公司 | 大环整合酶抑制剂 |
EP2509949B1 (en) | 2009-12-07 | 2014-04-23 | University Of Georgia Research Foundation, Inc. | Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications |
BR112012024796A2 (pt) | 2010-04-02 | 2016-06-07 | Janssen R&D Ireland | inibidores de integrase macrocíclicos |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
PE20141558A1 (es) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih |
EP2880017B1 (en) * | 2012-08-03 | 2016-10-05 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
CZ304984B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru |
CZ304983B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Způsob výroby a nové intermediáty syntézy elvitegraviru |
DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
EP2938185B1 (en) | 2012-12-26 | 2020-04-29 | Société des Produits Nestlé S.A. | Low density coated animal litter compositions |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
ES2906115T3 (es) | 2013-04-18 | 2022-04-13 | Boehringer Ingelheim Int | Composición farmacéutica, métodos de tratamiento y usos de la misma |
CZ307255B6 (cs) * | 2013-07-11 | 2018-05-02 | Zentiva, K.S. | Nový způsob přípravy elvitegraviru |
PT3019503T (pt) | 2013-07-12 | 2017-11-27 | Gilead Sciences Inc | Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv |
NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
WO2016081464A1 (en) | 2014-11-17 | 2016-05-26 | Nirogyone Therapeutics, Inc. | Monocarboxylate transport modulators and uses thereof |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
KR20190057158A (ko) | 2015-04-02 | 2019-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
WO2016193997A2 (en) * | 2015-06-03 | 2016-12-08 | Msn Laboratories Private Limited | Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof |
US10881077B2 (en) | 2015-10-23 | 2021-01-05 | Société des Produits Nestlé S.A. | Low density pet litters and methods of making such pet litters |
RU2654062C2 (ru) * | 2016-07-14 | 2018-05-16 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3472859A (en) | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
JPS4826772A (es) | 1971-08-11 | 1973-04-09 | ||
DE3501247A1 (de) * | 1985-01-16 | 1986-07-17 | Bayer Ag, 5090 Leverkusen | Aminoacrylsaeure-derivate |
US5591744A (en) * | 1987-04-16 | 1997-01-07 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
NO885426L (no) * | 1987-12-11 | 1989-06-12 | Dainippon Pharmaceutical Co | Kinolinderivater, samt fremgangsmaate ved fremstilling derav. |
US4920120A (en) * | 1988-01-25 | 1990-04-24 | Warner-Lambert Company | Antibacterial agents |
DE3934082A1 (de) * | 1989-10-12 | 1991-04-18 | Bayer Ag | Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel |
DE4015299A1 (de) * | 1990-05-12 | 1991-11-14 | Bayer Ag | Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten |
IL100555A (en) | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
JP2993316B2 (ja) | 1992-05-27 | 1999-12-20 | 宇部興産株式会社 | アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤 |
NO304832B1 (no) | 1992-05-27 | 1999-02-22 | Ube Industries | Aminokinolonderivater samt middel mot HIV |
JPH06199635A (ja) | 1992-12-28 | 1994-07-19 | Kanebo Ltd | 化粧料 |
JPH06199835A (ja) | 1993-01-08 | 1994-07-19 | Hokuriku Seiyaku Co Ltd | 8−ジフルオロメトキシキノリン−3−カルボン酸誘導体 |
JPH06271568A (ja) | 1993-03-22 | 1994-09-27 | Hokuriku Seiyaku Co Ltd | 7−フェニルピペラジニルキノリン−3−カルボン酸誘導体 |
US5686482A (en) * | 1994-04-28 | 1997-11-11 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl) benzamide derivative |
RU2140919C1 (ru) * | 1994-07-18 | 1999-11-10 | Убе Индастриз Лтд. | Производные 8-трифторметилхинолинкарбоновой кислоты, фармацевтическая композиция и способ ингибирования вируса иммунодефицита |
JP2930539B2 (ja) | 1994-07-18 | 1999-08-03 | 三共株式会社 | トリフルオロメチルキノリンカルボン酸誘導体 |
JPH08183776A (ja) | 1994-12-28 | 1996-07-16 | Hideaki Yamaguchi | 金属の表面保護剤ならびにそれを用いた製造方法 |
US6303611B1 (en) * | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
JP4121151B2 (ja) | 1996-04-12 | 2008-07-23 | アメリカ合衆国 | 抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物 |
US6287550B1 (en) * | 1996-12-17 | 2001-09-11 | The Procter & Gamble Company | Animal care system and litter with reduced malodor impression |
US5989451A (en) * | 1997-02-07 | 1999-11-23 | Queen's University At Kingston | Compounds and methods for doping liquid crystal hosts |
FR2761687B1 (fr) * | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Icam−1産生阻害剤 |
KR20010013377A (ko) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
TW527355B (en) * | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
JPH1184556A (ja) | 1997-09-08 | 1999-03-26 | Konica Corp | ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法 |
GB9721964D0 (en) | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
GB9807903D0 (en) | 1998-04-14 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
DE19950898A1 (de) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
PE20011349A1 (es) | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
US6730682B2 (en) * | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
EP1326610B1 (en) | 2000-10-12 | 2006-11-15 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
US20050010048A1 (en) | 2000-10-12 | 2005-01-13 | Linghang Zhuang | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors |
WO2002048113A1 (en) * | 2000-12-14 | 2002-06-20 | The Procter & Gamble Company | Cyclization process step in the making of quinolones and naphthyridines |
US20040198716A1 (en) | 2001-02-05 | 2004-10-07 | Dorit Arad | Cysteine protease inhimbitors |
MXPA03007765A (es) | 2001-03-01 | 2003-12-08 | Shionogi & Co | Compuestos heteroarilo que contienen nitrogeno, que tienen actividad inhibitoria contra virus de inmunodeficiencia humana integrasa. |
JP4518302B2 (ja) | 2001-03-19 | 2010-08-04 | 日本化薬株式会社 | 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体 |
JP2002293745A (ja) | 2001-03-29 | 2002-10-09 | St Marianna Univ School Of Medicine | 慢性関節リウマチ治療剤 |
JP3980842B2 (ja) | 2001-05-11 | 2007-09-26 | バブコック日立株式会社 | アンモニア含有排水の浄化装置および浄化方法 |
JP2003065807A (ja) | 2001-08-29 | 2003-03-05 | Mitsubishi Electric Corp | プロセスデータのトレンド表示方法および装置 |
JP3913037B2 (ja) | 2001-10-30 | 2007-05-09 | 三菱電機株式会社 | 赤外線検出器 |
TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
SK2662004A3 (sk) * | 2002-11-20 | 2005-06-02 | Japan Tobacco, Inc. | Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz |
JP2004253231A (ja) | 2003-02-20 | 2004-09-09 | Pioneer Electronic Corp | プラズマディスプレイパネル |
US7531554B2 (en) * | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
EP2332538A1 (en) * | 2004-05-21 | 2011-06-15 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
WO2007102499A1 (ja) | 2006-03-06 | 2007-09-13 | Japan Tobacco Inc. | 4-オキソキノリン化合物の製造方法 |
AP2914A (en) * | 2006-03-06 | 2014-05-31 | Japan Tobacco Inc | Method for producing 4-oxoquinoline compound |
TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
WO2008033836A2 (en) * | 2006-09-12 | 2008-03-20 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
AU2008299931B2 (en) * | 2007-09-12 | 2013-01-10 | Concert Pharmaceuticals, Inc. | Deuterated 4 -oxoquinoline derivatives for the treatment of HIV infection |
WO2009089263A2 (en) | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
SI23420A (sl) | 2010-07-22 | 2012-01-31 | Institut "Jožef Stefan" | Kostni vsadki z večslojno prevleko in postopek njihove priprave |
US11347056B2 (en) | 2018-08-22 | 2022-05-31 | Microsoft Technology Licensing, Llc | Foveated color correction to improve color uniformity of head-mounted displays |
US11996736B2 (en) | 2018-08-23 | 2024-05-28 | Lg Innotek Co., Ltd. | Sensing device |
WO2020040561A1 (ko) | 2018-08-24 | 2020-02-27 | 한온시스템 주식회사 | 차량용 공조장치 |
-
2003
- 2003-11-20 SK SK266-2004A patent/SK2662004A3/sk not_active Application Discontinuation
- 2003-11-20 EP EP10011216A patent/EP2272516A3/en not_active Withdrawn
- 2003-11-20 NZ NZ533641A patent/NZ533641A/en not_active IP Right Cessation
- 2003-11-20 SI SI200331707T patent/SI1564210T1/sl unknown
- 2003-11-20 IL IL16254803A patent/IL162548A0/xx unknown
- 2003-11-20 US US10/492,833 patent/US7176220B2/en active Active
- 2003-11-20 CA CA2470365A patent/CA2470365C/en not_active Expired - Lifetime
- 2003-11-20 PT PT03811532T patent/PT1564210E/pt unknown
- 2003-11-20 WO PCT/JP2003/014773 patent/WO2004046115A1/ja active IP Right Grant
- 2003-11-20 BR BRPI0306214-7A patent/BRPI0306214B1/pt active IP Right Grant
- 2003-11-20 TR TR2004/01663T patent/TR200401663T1/xx unknown
- 2003-11-20 KR KR1020047010082A patent/KR100665919B1/ko active Protection Beyond IP Right Term
- 2003-11-20 TW TW092132527A patent/TWI248928B/zh not_active IP Right Cessation
- 2003-11-20 PE PE2003001176A patent/PE20040840A1/es active IP Right Grant
- 2003-11-20 EP EP18166352.7A patent/EP3406596A1/en not_active Withdrawn
- 2003-11-20 DE DE60329318T patent/DE60329318D1/de not_active Expired - Lifetime
- 2003-11-20 EP EP03811532A patent/EP1564210B9/en not_active Expired - Lifetime
- 2003-11-20 ES ES03811532T patent/ES2329240T3/es not_active Expired - Lifetime
- 2003-11-20 MY MYPI20034478A patent/MY136173A/en unknown
- 2003-11-20 EP EP22158433.7A patent/EP4059923A1/en active Pending
- 2003-11-20 DK DK03811532.5T patent/DK1564210T5/da active
- 2003-11-20 AR ARP030104286A patent/AR042095A1/es active IP Right Grant
- 2003-11-20 AT AT03811532T patent/ATE443048T1/de active
- 2003-11-20 AU AU2003302029A patent/AU2003302029B8/en active Active
- 2003-11-20 EP EP09169859A patent/EP2161258A3/en not_active Withdrawn
- 2003-11-20 CZ CZ2004764A patent/CZ2004764A3/cs unknown
-
2004
- 2004-06-08 ZA ZA2004/04537A patent/ZA200404537B/en unknown
- 2004-06-16 IL IL162548A patent/IL162548A/en active Protection Beyond IP Right Term
- 2004-07-02 MX MXPA04006553A patent/MXPA04006553A/es active IP Right Grant
- 2004-07-14 NO NO20043004A patent/NO327098B1/no not_active IP Right Cessation
-
2006
- 2006-01-18 HK HK06100829.1A patent/HK1080852A1/xx not_active IP Right Cessation
- 2006-06-05 US US11/446,128 patent/US8232401B2/en active Active
-
2009
- 2009-12-11 CY CY20091101301T patent/CY1110690T1/el unknown
-
2012
- 2012-06-20 US US13/528,688 patent/US20130172344A1/en not_active Abandoned
- 2012-07-03 AR ARP120102410A patent/AR087046A2/es unknown
-
2013
- 2013-07-12 LT LTPA2013018C patent/LTPA2013018I1/lt unknown
- 2013-11-07 NO NO2013015C patent/NO2013015I2/no unknown
- 2013-11-07 HU HUS1300066C patent/HUS1300066I1/hu unknown
- 2013-11-11 LU LU92307C patent/LU92307I2/fr unknown
- 2013-11-12 FR FR13C0061C patent/FR13C0061I2/fr active Active
- 2013-11-14 BE BE2013C063C patent/BE2013C063I2/fr unknown
- 2013-11-18 CY CY2013043C patent/CY2013043I1/el unknown
-
2014
- 2014-06-10 US US14/301,083 patent/US20150174117A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/409,728 patent/US20200101061A1/en not_active Abandoned
-
2022
- 2022-05-13 US US17/663,391 patent/US20230190730A1/en not_active Abandoned
- 2022-07-22 NO NO2022032C patent/NO2022032I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040840A1 (es) | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih | |
PE20060737A1 (es) | 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION | |
PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
PE20040479A1 (es) | Inhibidores de proteasa del vih y composiciones que los contienen | |
PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
ES2159839T3 (es) | Derivados del propano, su preparacion y su uso. | |
MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
PE20010685A1 (es) | Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 | |
PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
PE20080688A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion | |
PE20200608A1 (es) | Nuevos derivados de azaquinolina | |
UY26872A1 (es) | Derivados de la 4- fenil piridina | |
PA8607001A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
PE20070462A1 (es) | Compuestos derivados de fenilaminopropanol | |
UY27109A1 (es) | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b | |
PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
PE55098A1 (es) | Derivados de 6-fenilpiridil-2-amina | |
PE20040168A1 (es) | Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas | |
PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
PE20140608A1 (es) | Analogos de nucleotidos sustituidos | |
PA8495101A1 (es) | Derivados de 13-metileritromicina | |
PE20061370A1 (es) | Proceso para preparar oxindoles y tio-oxindoles 3,3- disustituidos | |
ES2054846T3 (es) | Derivados de un acido carboxilico sustituido, procedimientos para su preparacion y fungicidas agricolas u horticolas que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |